Pearl Diagnostics, led by Johns Hopkins University Professor Kieren Marr, plans to use the funding to focus on manufacturing, in preparation for the commercial launch of its urine antigen test for fungal pneumonia. The test is already approved for sale in Europe and the company is currently seeking approval in the United States as well. Pearl plans on submitting its test for FDA approval at the end of this year.

Release date